You just read:

Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with relapsing multiple sclerosis

News provided by

Novartis Pharmaceuticals Corporation

Sep 12, 2018, 17:02 ET